N/A N=180 Efficacy Trial of a Dissonance Based Eating Disorder Program
Eating Disorder
Primary: Rosenberg Self-Esteem Scale (RSE). — 22.71; 22.50; 22.62 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=186 A Treatment for Severe Inflammatory Acne Subjects
Acne Vulgaris
Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions
N/A N=49 Bifocal & Atropine in Myopia (BAM) Study
Refractive Errors
Primary: Refractive Error Progression — -3.50 Diopter — p=0.70
Phase 4 N=69 Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
Secondary Hyperparathyroidism Due to Renal Causes · Vitamin D Insufficiency · CKD Stage 3
Primary: Incidence and Severity of Treatment-Emergent Adverse Events (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. — 39; 12; 13; 10…
Phase 2 N=57 Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 46.4; 18.0 percent change
N/A N=6,135 mHealth Screening to Prevent Strokes
Atrial Fibrillation
Primary: Incidence of Newly Diagnosed AF in the Immediate vs Delayed Monitoring Group — 53; 12 Participants
Phase 2 N=82 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Peripheral T-Cell Lymphoma
Primary: Progression-free Survival After ASCT — 0.58; 0.77; 0.62 proportion of participants
Phase 2 N=151 A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
Diabetes · Obesity
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity — 5; 4; 10; 9 Participants
Phase 2 N=86 Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Leukemia · Myelodysplastic Syndrome · Non-Hodgkins Lymphoma
Primary: Progression Free Survival/PFS at 1 Year Post UCBT. — 84 percentage of participants
Phase 2 N=433 Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Hypertension, Ocular
Primary: Change From Baseline in Study Eye Mean Diurnal IOP at the Week 4 — -7.79; -8.28; -8.70; -7.41 mmHg — p=0.2666
N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
N/A N=6 Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
Diabetes Type 2 · Diabetes Mellitus
Primary: Temperature as a Source of Unwanted Variation When Using Freestyle Libre Glucose Sensors
Phase 4 N=29 Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Protein Expression) — 0.63; 0.33; 1.58; 0.90 ng/mL in serum
Phase 2 N=225 Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
Covid19
Primary: Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic…
N/A N=103 Developing Genetic Education for Smoking Cessation
Tobacco Smoking
Primary: Knowledge of Genetic Contributions to Smoking — 5.25; 3.73; 7.04; 4.03 score on a scale — p=<0.01